

**NAME:** Martin L. Pall

**DATE:** September 2009

[martin\\_pall@wsu.edu](mailto:martin_pall@wsu.edu)

Phone: 503-232-3883

## **EDUCATION**

Institutions, degrees, dates

<u>Organization and Location</u>	<u>Degree</u>	<u>Date</u>
Johns Hopkins University Baltimore, MD	B.A.	1962
California Institute of Technology, Pasadena, CA	Ph.D.	1968

## **EXPERIENCE**

Positions and dates

Reed College, Portland, OR	1967-72	Assistant Professor of Biology
Department of Botany, Indiana University, Bloomington, IN	May-June 1971	Visiting Research Associate
Program in Genetics and Depart- ment of Chemistry, Washington State University, Pullman, WA	9/16/72- 9/15/75	Assistant Professor of Genetics and Chemistry
Program in Genetics and Program in Biochemistry/Biophysics, Wash- ington State University, Pullman, WA	4/12/73	Elected to Graduate Faculty in Genetics and Biochemistry
	9/16/75- 1/31/81	Associate Professor of Genetics and Biochemistry
Program in Genetics, Washington State University, Pullman, WA	9/16/78- 9/15/79	Acting Chairman, Program in Genetics
Department of Physiology, Yale University, New Haven, CT	9/16/79- 9/15/80	Visiting Associate Professor (during professional leave)
Departments of Genetics and Cell Biology and Biochemistry/ Biophysics, Washington State University, Pullman, WA	2/1/81- 9/15/83	Associate Professor of Genetics and Cell Biology and Biochemistry
	9/16/83- 8/15/96	Professor of Genetics and Cell Biology and Biochemistry
Department of Pharmacology, University of California, San Francisco, Ca	5/15/86 12/31/86	Adjunct Professor of Pharmacology (professional leave)

Washington State University, Vancouver, WA	8/16/94- 5/16/96	Coordinator of Sciences
Department of Biochemistry/Biophysics and Basic Medical Sciences Program	8/16/96-99	Professor of Biochemistry and Basic Medical Sciences
School of Molecular Biosciences and Basic Medical Sciences Program	8/16/99- 8/15/08	Professor of Biochemistry and Basic Medical Sciences
Professor Emeritus of Biochemistry and Basic Medical Sciences, WSU and Research Director, The Tenth Paradigm Research Group, Portland, OR	8/15/08-	

### **CURRENT WEB SITE:**

thetenthparadigm.org

### **MEMBERSHIPS**

#### **HONOR SOCIETIES**

Phi Beta Kappa  
Alpha Epsilon Delta  
Sigma Xi

Member of Panel of Advisors of Environmental Law Centre in London  
Clinician of the Month, Healthcomm International (October, 1999),  
Member Scientific Advisory Board of Ariston Pharmaceuticals

#### **PROFESSIONAL SOCIETIES AND OTHER HONORS**

American Society of Biochemistry and Molecular Biology  
International Association for Chronic Fatigue Syndrome

#### **Publications from 2001:**

59. Pall, M. L. 2001. Cobalamin used in chronic fatigue syndrome therapy is a nitric oxide scavenger. *Journal of Chronic Fatigue Syndr* 8(2):39-44.
60. Pall M. L, Satterlee J. D., 2001. Elevated nitric oxide/peroxynitrite mechanism for the common etiology of multiple chemical sensitivity, chronic fatigue syndrome and posttraumatic stress disorder. *Annals of the New York Academy of Sciences* 933:323-329.
61. Pall M. L. 2001. Common etiology of posttraumatic stress disorder, fibromyalgia, chronic fatigue syndrome and multiple chemical sensitivity via elevated nitric oxide/peroxynitrite. *Med Hypoth* 57:139-145.
62. Pall M. L. 2002. The levels of nitric oxide synthase product, citrulline, are elevated in the sera of chronic fatigue syndrome patients. *J Chronic Fatigue Syndr* 10(3/4):37-41..
63. Pall M. L. 2002. NMDA sensitization and stimulation by peroxynitrite, nitric oxide and organic solvents as the mechanism of chemical sensitivity in multiple chemical sensitivity. *FASEB J.* 16:1407-1417.
64. Pall, M. L. 2002 Chronic fatigue syndrome/myalgia encephalomyelitis. *Br J Gen Pract* 52:762.
65. Smirnova I.V., Pall M.L. 2003 Elevated levels of protein carbonyls in sera of chronic fatigue syndrome patients. *Mol Cell Biochem* 248:93-95.

66. Pall M. L. 2003. Elevated nitric oxide/peroxynitrite theory of multiple chemical sensitivity: Central role of N-methyl-D-aspartate receptors in the sensitivity mechanism. *Environ Health Perspect* 111:1461-1464.
67. Pall M. L. 2003 Long delayed sequelae of organophosphate exposure. *Arch Env Health* 58:605.
68. Pall M. L. 2004 The simple truth about multiple chemical sensitivity. *Environ Health Perspect* 112:A266-A267.
69. Pall M. L., Anderson J. H. 2004 The vanilloid receptor as a putative target of diverse chemicals in multiple chemical sensitivity. *Arch Environ Health* 59:363-375.
70. Pall M. L. 2005 Chronic fatigue syndrome and nitric oxide: giving credit where credit is due. *Med Hypoth* 65:631-633..
71. Pall M. L. 2006 Elevated nitric oxide/peroxynitrite neurochemical mechanism of multiple chemical sensitivity. In *Neurochemistry*, Kohji Fukunaga, ed., in press.
72. Pall M. L. 2005 Multiple chemical sensitivity: towards the end of controversy. *Townsend Let Doctors Patients* Aug/Sept 2005:52-56.
73. Pall M. L. 2007 Explaining 'Unexplained Illnesses': Disease Paradigm for Chronic Fatigue Syndrome, Multiple Chemical Sensitivity, Fibromyalgia, Posttraumatic Stress Disorder, Gulf War Syndrome and Others, Haworth Medical Press.
74. Pall M. L. 2006 The NO/ONOO<sup>-</sup> Cycle as the Cause of Fibromyalgia and Related Illnesses: Etiology, Explanation and Effective Therapy. In, *New Research in Fibromyalgia*, Nova Science Publishers, Hauppauge, NY, pp 39-61.
75. Pall M. L., Bedient S. A. 2007 The NO/ONOO<sup>-</sup> Cycle as the Etiologic Mechanism of Tinnitus, *Int Tinnitus J* 13:99-104.
76. Pall M. L. 2007 "Explaining 'Unexplained Illness': Disease Paradigm for Chronic Fatigue Syndrome, Multiple Chemical Sensitivity, Fibromyalgia, Post-Traumatic Stress Disorder, Gulf War Syndrome and Others", 16 Chapter book, Harrington Park (Haworth) Press.
77. Pall M. L. 2007 Nitric oxide synthase partial uncoupling as a key switching mechanism for the NO/ONOO<sup>-</sup> cycle. *Med Hypoth*
78. Pall M. L. 2008 Post-radiation syndrome as a NO/ONOO<sup>-</sup> cycle, chronic fatigue syndrome-like disease. *Med Hypoth* 78:537-541.
79. Pall M. L. 2008 Does sauna therapy used to treat multiple chemical sensitivity and other diseases act by increasing availability of tetrahydrobiopterin? *Med Hypoth* 73:610-613..
80. Pall M. L. 2009 Multiple chemical sensitivity: Toxicological questions and mechanisms. In *General and Applied Toxicology*, 3<sup>rd</sup> Edition, Bryan Ballantyne, Timothy C. Marrs, Tore Syversen, Eds., John Wiley & Sons, pp. 2303-2352.
81. Pall M. L. 2009 The NO/ONOO<sup>-</sup> Vicious Cycle Mechanism as the Cause of Chronic Fatigue Syndrome/Myalgic Encephalomyelitis, In *Chronic Fatigue Syndrome: Symptoms, Causes and Prevention*, Edita Svoboda and Kristof Zelenjick, eds., Nova Publishers, in press.
82. Pall M. L. 2010 How Can We Cure NO/ONOO<sup>-</sup> Cycle Diseases? Approaches to curing chronic fatigue syndrome/myalgic encephalomyelitis, fibromyalgia, multiple chemical sensitivity, Gulf War syndrome and possible many others, *The Townsend Letter for Doctors and Patients*, Feb 2010, 75-84
83. Pall M. L. Excessive NMDA Activity as a Toxicant Endpoint: Pesticides, Organic Solvents and Other Toxicants, in preparation.